MET: A promising anticancer therapeutic target

Solange Peters, Alex Adjei

Research output: Contribution to journalReview article

203 Citations (Scopus)

Abstract

The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Thus, MET has emerged as an attractive target for cancer therapy. Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clinical trials. In general, initial results from these studies indicate only a modest benefit in unselected populations. In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.

Original languageEnglish (US)
Pages (from-to)314-326
Number of pages13
JournalNature Reviews Clinical Oncology
Volume9
Issue number6
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

Neoplasms
Therapeutics
Drug Resistance
Radiotherapy
Biomarkers
Clinical Trials
Drug Therapy
Growth
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology

Cite this

MET : A promising anticancer therapeutic target. / Peters, Solange; Adjei, Alex.

In: Nature Reviews Clinical Oncology, Vol. 9, No. 6, 01.06.2012, p. 314-326.

Research output: Contribution to journalReview article

@article{62f44f944743430d92f5fe6ff3ba84ee,
title = "MET: A promising anticancer therapeutic target",
abstract = "The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Thus, MET has emerged as an attractive target for cancer therapy. Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clinical trials. In general, initial results from these studies indicate only a modest benefit in unselected populations. In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.",
author = "Solange Peters and Alex Adjei",
year = "2012",
month = "6",
day = "1",
doi = "10.1038/nrclinonc.2012.71",
language = "English (US)",
volume = "9",
pages = "314--326",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - MET

T2 - A promising anticancer therapeutic target

AU - Peters, Solange

AU - Adjei, Alex

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Thus, MET has emerged as an attractive target for cancer therapy. Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clinical trials. In general, initial results from these studies indicate only a modest benefit in unselected populations. In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.

AB - The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Thus, MET has emerged as an attractive target for cancer therapy. Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clinical trials. In general, initial results from these studies indicate only a modest benefit in unselected populations. In this Review, we discuss current challenges in developing MET inhibitors-including identification of predictive biomarkers-as well as the most-efficient ways to combine these drugs with other targeted agents or with classic chemotherapy or radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84861733799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861733799&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2012.71

DO - 10.1038/nrclinonc.2012.71

M3 - Review article

C2 - 22566105

AN - SCOPUS:84861733799

VL - 9

SP - 314

EP - 326

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 6

ER -